Updates in Immunotherapy for Pancreatic Cancer

被引:0
|
作者
Chick, Robert Connor [1 ]
Pawlik, Timothy M. [1 ]
机构
[1] Ohio State Univ, Dept Surg, Wexner Med Ctr, Columbus, OH 43210 USA
关键词
pancreatic cancer; immunotherapy; personalized; tumor microenvironment; immune checkpoint inhibitor; cancer vaccine; T-CELLS; TUMOR MICROENVIRONMENT; CHECKPOINT INHIBITORS; STROMAL INFLAMMATION; NEOADJUVANT THERAPY; OPEN-LABEL; COMBINATION; TRIAL; PEMBROLIZUMAB; FOLFIRINOX;
D O I
10.3390/jcm13216419
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with limited effective therapeutic options. Due to a variety of cancer cell-intrinsic factors, including KRAS mutations, chemokine production, and other mechanisms that elicit a dysregulated host immune response, PDAC is often characterized by poor immune infiltration and an immune-privileged fibrotic stroma. As understanding of the tumor microenvironment (TME) evolves, novel therapies are being developed to target immunosuppressive mechanisms. Immune checkpoint inhibitors have limited efficacy when used alone or with radiation. Combinations of immune therapies, along with chemotherapy or chemoradiation, have demonstrated promise in preclinical and early clinical trials. Despite dismal response rates for immunotherapy for metastatic PDAC, response rates with neoadjuvant immunotherapy are somewhat encouraging, suggesting that incorporation of immunotherapy in the treatment of PDAC should be earlier in the disease course. Precision therapy for PDAC may be informed by advances in transcriptomic sequencing that can identify immunophenotypes, allowing for more appropriate treatment selection for each individual patient. Personalized and antigen-specific therapies are an increasing topic of interest, including adjuvant immunotherapy using personalized mRNA vaccines to prevent recurrence. Further development of personalized immune therapies will need to balance precision with generalizability and cost.
引用
收藏
页数:18
相关论文
共 50 条
  • [21] Clinical immunotherapy in pancreatic cancer
    Ye, Xiaorong
    Yu, Yue
    Zheng, Xiaohu
    Ma, Hongdi
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (04)
  • [22] Tumor microenvironment in chemoresistance, metastasis and immunotherapy of pancreatic cancer
    Wang, Shunda
    Li, Yatong
    Xing, Cheng
    Ding, Cheng
    Zhang, Hanyu
    Chen, Lixin
    You, Lei
    Dai, Menghua
    Zhao, Yupei
    AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 10 (07): : 1937 - 1953
  • [23] Combination immunotherapy for pancreatic cancer: challenges and future considerations
    Gossling, Gustavo C. L.
    Zhen, David B.
    Pillarisetty, Venu G.
    Chiorean, E. Gabriela
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2022, 18 (11) : 1173 - 1186
  • [24] Landmark Series: Immunotherapy and Targeted Therapy for Pancreatic Cancer
    Rocha, Flavio G.
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (03) : 1400 - 1406
  • [25] Exploring the Immunoresponse in Bladder Cancer Immunotherapy
    Ruiz-Lorente, Inmaculada
    Gimeno, Lourdes
    Lopez-Abad, Alicia
    Cubillana, Pedro Lopez
    Aparicio, Tomas Fernandez
    Egea, Lucas Jesus Asensio
    Aviles, Juan Moreno
    Iniguez, Gloria Donate
    Martinez-Valls, Pablo Luis Guzman
    Server, Gerardo
    Escudero-Bregante, Jose Felix
    Ferri, Belen
    Campillo, Jose Antonio
    Pons-Fuster, Eduardo
    Hernandez, Maria Dolores Martinez
    Martinez-Sanchez, Maria Victoria
    Ceballos, Diana
    Minguela, Alfredo
    CELLS, 2024, 13 (23)
  • [26] Glycoconjugate Nanoparticle-Based Systems in Cancer Immunotherapy: Novel Designs and Recent Updates
    Barchi, Joseph J., Jr.
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [27] The dark side of immunotherapy: pancreatic cancer
    Mucciolo, Gianluca
    Roux, Cecilia
    Scagliotti, Alessandro
    Brugiapaglia, Silvia
    Novelli, Francesco
    Cappello, Paola
    CANCER DRUG RESISTANCE, 2020, 3 (03) : 491 - 520
  • [28] Immunotherapy for pancreatic cancer: present and future
    Aroldi, Francesca
    Zaniboni, Alberto
    IMMUNOTHERAPY, 2017, 9 (07) : 607 - 616
  • [29] New avenues for the treatment of immunotherapy-resistant pancreatic cancer
    de Oliveira Silva, Luis Guilherme
    Lemos, Fabian Fellipe Bueno
    Luz, Marcel Silva
    Pinheiro, Samuel Luca Rocha
    dos Santos Calmon, Mariana
    Santos, Gabriel Lima Correa
    Rocha, Gabriel Reis
    de Melo, Fabricio Freire
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 16 (04) : 1134 - 1153
  • [30] Recent advances in immunotherapy for pancreatic cancer
    Chi, Jeffrey
    Patel, Rajvi
    Rehman, Hasan
    Goyal, Shreya
    Saif, Muhammad Wasif
    JOURNAL OF CANCER METASTASIS AND TREATMENT, 2020, 6